CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 1,300 enrolled
Drug / intervention
Pacemaker Medtronic EnRhythmdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00262119
NCT00262119Phase 4Completed
CompareCT.gov

MINERVA: MINimizE Right Ventricular Pacing to Prevent Atrial Fibrillation and Heart Failure

Medtronic Cardiac Rhythm and Heart Failure·interventional·Posted Dec 6, 2005·Updated Jul 2, 2025

In Brief

A Phase 4 clinical trial evaluating Pacemaker Medtronic EnRhythm for Atrial Fibrillation and Heart Failure, Congestive. Completed, enrolled 1,300 participants across 1 site.

Detailed Summary

The aim of this study is to test the impact of the managed ventricular pacing (MVP) mode and atrial preventive and antitachycardia pacing therapies on the reduction of a composite clinical outcome composed of any death, permanent atrial fibrillation, and cardiovascular hospitalizations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation, Heart Failure, Congestive
CountriesItaly
Collaborators--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 6, 2005
Enrollment StartFeb 1, 2006
Primary CompletionApr 1, 2012
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 20.6 years ago

Interventions

Pacemaker Medtronic EnRhythmdevice

Pacemaker specific programming